$2750 | Single User
$5500 | Site License
$8250 | Enterprise License

Renal cell carcinoma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

Published by Delve Insight: 10 Oct 2017 | 139044 | In Stock

Introduction

DelveInsight “Renal cell carcinoma - Epidemiology Forecast To 2025” provides an overview of the epidemiology trends of Renal cell carcinoma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Renal cell carcinoma prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Renal cell carcinoma. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Scope of the Report

The Report includes the prevalent population and how will it change over the next eight years.

Prevalent or incident cases segmented by age and sex.

Coverage of key Renal cell carcinoma subpopulations and its prevalent or incident cases

The key differences in epidemiology patterns across the seven market segments

Key Coverage and Benefits

The report will help in developing business strategies by understanding the trends shaping and driving the global Renal cell carcinoma market.

Identifying prevalent patient populations as well as risk factors in the global Renal cell carcinoma market will help to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the best opportunities for Renal cell carcinoma therapeutics in each of the markets covered.

Table of Contents
for Renal cell carcinoma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

  • 1. Report Introduction

    2. Snapshot of Total Prevalent or Incident cases by 7 MM

    3. Executive Summary

    • Key Findings

    4. Renal cell carcinoma Overview

    • Renal cell carcinoma Definition

    • Pathophysiology

    • Symptoms

    5. Etiology

    6. Risk Factors Associated with Renal cell carcinoma

    7. Disease Burden & Unmet Need in the Market

    8. Epidemiology and Patient Populations

    • Key Findings

    • Key Sources used and Forecast Methodology

    • Prevalent Cases and Incident Cases-2015-2025

    • Prevalent & Incident Cases by Category-2015-2025

    • Age-Specific Prevalent/ Incident Cases of Renal cell carcinoma

    • Sex-Specific Prevalent/Incident Cases of Renal cell carcinoma

    • Disease Type Specific Prevalent/Incident Cases of Renal cell carcinoma

    9. Prevalent & Incident Cases by 7 MM-2015-2025

    • Renal cell carcinoma Epidemiology of United States-2025

    • Renal cell carcinoma Epidemiology of United Kingdom-2025

    • Renal cell carcinoma Epidemiology of Germany-2025

    • Renal cell carcinoma Epidemiology of France-2025

    • Renal cell carcinoma Epidemiology of Spain-2025

    • Renal cell carcinoma Epidemiology of Italy-2025

    • Renal cell carcinoma Epidemiology of Japan-2025

    10. Key Takeaways

    11. Appendix

    12. Report Methodology

    13. Consulting Services

List Of Tables
in Renal cell carcinoma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

Table 1: Clinical subtypes of Indication

Table 2: Risk Factors

Table 3: Prevalence cases (%) Region wise

Table 4: Sources used for forecasting the data

Table 5: Renal cell carcinoma Global Epidemiology, (2015-2025)

Table 6: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), US (2015-2025)

Table 7: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), US (2015-2025)

Table 8: Prevalent Cases By Renal cell carcinoma Sub-population, US (2015-2025)

Table 9: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), United Kingdom (2015-2025)

Table 10: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), United Kingdom (2015-2025)

Table 11: Prevalent Cases By Renal cell carcinoma Sub-population, United Kingdom (2015-2025)

Table 12: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Germany (2015-2025)

Table 13: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Germany (2015-2025)

Table 14: Prevalent Cases By Renal cell carcinoma Sub-population, Germany (2015-2025)

Table 15: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), France (2015-2025)

Table 16: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), France (2015-2025)

Table 17: Prevalent Cases By Renal cell carcinoma Sub-population, France (2015-2025)

Table 18: Prevalent Cases of Renal cell carcinoma(Ages =XX Years), Italy (2015-2025)

Table 19: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Italy (2015-2025)

Table 20: Prevalent Cases By Renal cell carcinoma Sub-population, Italy (2015-2025)

Table 21: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Spain (2015-2025)

Table 22: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Spain (2015-2025)

Table 23: Prevalent Cases By Renal cell carcinoma Sub-population, Spain (2015-2025)

Table 24: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Japan (2015-2025)

Table 25: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Japan (2015-2025)

Table 26: Prevalent Cases By Renal cell carcinoma Sub-population, Japan (2015-2025)

List Of Figures, Charts and Diagrams
in Renal cell carcinoma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

Figure 1: Prevalence cases (%) Region wise

Figure 2: Sources used for forecasting the data

Figure 3: Renal cell carcinoma Global Epidemiology, (2015-2025)

Figure 4: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), US (2015-2025)

Figure 5: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), US (2015-2025)

Figure 6: Prevalent Cases By Renal cell carcinoma Sub-population, US (2015-2025)

Figure 7: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), United Kingdom (2015-2025)

Figure 8: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), United Kingdom (2015-2025)

Figure 9: Prevalent Cases By Renal cell carcinoma Sub-population, United Kingdom (2015-2025)

Figure 10: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Germany (2015-2025)

Figure 11: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Germany (2015-2025)

Figure 12: Prevalent Cases By Renal cell carcinoma Sub-population, Germany (2015-2025)

Figure 13: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), France (2015-2025)

Figure 14: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), France (2015-2025)

Figure 15: Prevalent Cases By Renal cell carcinoma Sub-population, France (2015-2025)

Figure 16: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Italy (2015-2025)

Figure 17: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Italy (2015-2025)

Figure 18: Prevalent Cases By Renal cell carcinoma Sub-population, Italy (2015-2025)

Figure 19: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Spain (2015-2025)

Figure 20: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Spain (2015-2025)

Figure 21: Prevalent Cases By Renal cell carcinoma Sub-population, Spain (2015-2025)

Figure 22: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Japan (2015-2025)

Figure 23: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Japan (2015-2025)

Figure 24: Prevalent Cases By Renal cell carcinoma Sub-population, Japan (2015-2025)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

139044 | DIEI0338

Number of Pages

40

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Renal Failure Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care Inc. (U.S. Renal Care) is a healthcare service provider that offers in-center...
10 May 2016 by Global Data USD $250 More Info
Market Access Impact: Renal Cell Carcinoma (US)
IntroductionMarket barriers boost net share for 6 major RCC treatments in US. Is your brand one of t...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Market Access Impact: Renal Cell Carcinoma (EU5)
IntroductionMarket barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (US)
IntroductionOpdivo’s medical affairs team working overtime to engage oncologists. Is it paying off?O...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
Introduction4 medical affairs teams working hard to engage oncologists. Which one gets top marks? Eu...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care, Inc. (U.S. Renal Care) is a healthcare service provider that offers in-cente...
17 Mar 2016 by Global Data USD $250 More Info
NPS+ Renal Cell Carcinoma (US)
IntroductionTwo brands lead the RCC treatment market. How does your brand stack up?US oncologists ma...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
NPS+ Renal Cell Carcinoma (EU5)
IntroductionCompare 8 major RCC brands. Learn which one scores 6 times higher than any other?FirstVi...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
Renal Cell Carcinoma: KOL Insight
IntroductionWill new checkpoint inhibitors revive immunotherapy in RCC?Renal Cell Carcinoma: KOL Ins...
01 Feb 2015 by FirstWord Pharma USD $7,900 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Renal cell carcinoma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data